Crossmark

Predictors of residual hepatic reserve and hepatic decompensation in cirrhotic patients after ablated hepatocellular carcinoma treated by DDAs or systemic therapy

Crossref DOI link: https://doi.org/10.1186/s43066-021-00151-2

Published Online: 2021-10-16

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hanafy, Amr Shaaban https://orcid.org/0000-0003-2901-2614
Mohamed, Mohamed Sorour

Taleb, Mohamed Abu

Mohammed, H. M.

Ibrahim, Tarek M. H.

Saber, Sameh

Atia, Hesham A.
License Information

Text and Data Mining valid from 2021-10-16

Version of Record valid from 2021-10-16
More Information

Article History

Received: 9 June 2021

Accepted: 2 October 2021

First Online: 16 October 2021

Declarations

:

: All patients signed informed consent. The study was carried out following the Helsinki Declaration and was approved by the Zagazig University—Faculty of Medicine Ethical Committee, reference number is not available.

: Patients had agreed use of their data in research and publication without the appearance of their names.

: All authors declare that they have no competing interests.

Document is current

Any future updates will be listed below